Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China.

导出原文传递

翻译打印收藏纠错

作者： Helei,Hou ^[1] ; Yongjie,Wang ^[2] ; Dantong,Sun ^[3] ; Jingjuan,Zhu ^[1] ; Man,Jiang ^[1] ; Xuchen,Zhang ^[1] ; Na,Zhou ^[1] ; Chuantao,Zhang ^[1] ; Tianjun,Li ^[1] ; Xiaochun,Zhang ^[4]

作者单位： Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, 266000, Qingdao, Shandong, China. ^[1] Department of Thoracic Surgery, the Affiliated Hospital of Qingdao University, No. 59 Haier Road, 266000, Qingdao, Shandong, China. ^[2] Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China. ^[3] Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, 266000, Qingdao, Shandong, China. zxc9670@qdu.edu.cn. ^[4]

关键词 Immune checkpoint inhibitors Neoadjuvant therapy Non-small cell lung cancer PD-L1 Phase I study

主题词人类(Humans);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);紫杉酚(Paclitaxel);肿瘤辅助疗法(Neoadjuvant Therapy);铂(Platinum);肺肿瘤(Lung Neoplasms);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols)

DOI 10.1007/s10637-022-01324-5

PMID 36508040

发布时间 2023-05-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交